3 doses of mRNA Covid vaccines very effective against Omicron, Delta: Study

The study, from the US Centers for Disease Control and Prevention (CDC), found that boosters of mRNA Covid vaccines are 82 per cent effective in protecting against Omicron variant-associated ED visits

Covid-19 vaccines, Coronavirus vaccines, Vaccination
IANS New York
2 min read Last Updated : Jan 22 2022 | 2:40 PM IST

Three doses of mRNA Covid-19 vaccines, either Pfizer-BioNTech or Moderna, are effective in protecting against emergency department visits (ED) and hospitalisations associated with Omicron and Delta variations of the virus, claims a new study.

The study, from the US Centers for Disease Control and Prevention (CDC), found that boosters of mRNA Covid vaccines are 82 per cent effective in protecting against Omicron variant-associated ED visits.

It also found that booster shots are 90 per cent effective in protecting against Omicron variant-related hospitalisations.

"Our findings provide important evidence that booster shots are highly effective and those who are unvaccinated are at significantly greater risk of experiencing more severe Covid-19 outcomes and should get vaccinated and boostered as soon as possible," researcher Shaun Grannis from Indiana University, said.

The value of the third dose of an mRNA vaccine is significant as two doses were only 38 per cent effective in protecting against Omicron-related ED visits and only 57 per cent effective in protecting against Covid Omicron variant-related hospitalisations.

Boosters were even more effective against the Delta variant of Covid, protecting against 94 per cent of both Covid Delta variant associated ED visits and hospitalisations.

The CDC collaborated with six US healthcare systems to create the VISION network to assess Covid vaccine effectiveness.

--IANS

vc/sks/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Jan 22 2022 | 2:40 PM IST

Next Story